%0 Journal Article
%A Werner, Sebastian
%A Sekler, Julia
%A Gückel, Brigitte
%A la Fougère, Christian
%A Nikolaou, Konstantin
%A Pfannenberg, Christina
%A Preibsch, Heike
%A Engler, Tobias
%A Olthof, Susann-Cathrin
%T Influence of [18F]FDG-PET/CT on Clinical Management Decisions in Breast Cancer Patients-A PET/CT Registry Study.
%J Diagnostics
%V 13
%N 14
%@ 2075-4418
%C Basel
%I MDPI
%M DKFZ-2023-01540
%P 2420
%D 2023
%X There is a lack of evidence regarding the clinical impact of [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT, hereinafter referred to as PET/CT), especially regarding management changes and their link to overall survival. We analyzed 52 PET/CTs in 47 stage I-IV breast cancer patients, selected from a prospective oncological PET/CT registry. Indications for PET/CT were primary staging (n = 15), restaging (n = 17), and suspected recurrence (n = 20). PET/CT-induced management changes were categorized as major or minor. PET/CT-induced management changes in 41 of 52 scans (78.8
%K breast neoplasms (Other)
%K fluorodeoxyglucose F18 (Other)
%K positron emission tomography computed tomography (Other)
%K registries (Other)
%K survival rate (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37510164
%2 pmc:PMC10378166
%R 10.3390/diagnostics13142420
%U https://inrepo02.dkfz.de/record/277872